September 29, 2009
Abbott, J&J and Merck, Through a Spate of Deals, Expand in a Category With Built-In Buyers
BY JONATHAN D. ROCKOFF AND PETER LOFTUS
Amid rising concern about the threat of influenza pandemics, three big drug makers announced deals Monday that give them rights to new flu vaccines, placing bets on one of the pharmaceutical industry’s brightest, but riskiest, segments. The deals reflect the growing conviction among pharmaceutical executives that vaccines against a variety of maladies, long an industry stepchild, will become an increasingly important source of growth as they seek new sources of revenue to replace aging blockbusters that are poised to lose patent protection.
Vaccine sales are growing faster than sales of other prescription medicines and are largely immune to the generic …
Comment from Leslie
You have to subscribe to WSJ to read the rest of the article…but you can get the gist. All about money.